PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “AFRICA, WESTERN”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1987

[Kaposi's disease in Western Africa. 11 cases in Mali].

Eleven cases of Kaposi's angiosarcoma (ASK) were observed in Bamako over a 2 year period, representing one third of all malignant cutaneous tumours. There was a clear cut male prevalence. The average age of the patients was 32 years. The commonest sites of involvement were cutaneous, osseous, lymphatic and gastrointestinal. Special features of this series included prurigo preceding skin lesions, a single gastric localisation and involvement of the cavum. Rapid progression was observed in 3 cases, 2 of which had fatal outcomes. Two patients had multifocal disseminated disease at the outset. These cases were similar to ASK in patients with AIDS but our patients were not immunodepressed and LAV serology was negative. The results of chemotherapy were incomplete and transient. This series demonstrates the presence of acute, polyvisceral forms of ASK in Mali which may be classified as intermediary between the classical European or African ASK and the ASK observed in AIDS with positive serology in Central Africa.

Adult↗
PubMedDate not supplied

[Efficacy of UK 4271 (oxamniquine, Pfizer) in Schistosoma mansoni bilharziasis in western Africa (parasitological and serological study of 252 children)].

This study was conducted on 252 childrens afflicted with Schistosomiasis (S. mansoni and S. haematobium) living in endemic area and treated with doses of 15 mg/kg to 60 mg/kg of Oxamniquine. During eight months, parasitologic and serologic (Indirect fluorescent antibody test) controls were continued. A single per os dose of 15 mg/kg appears best and 87% cure rates were obtained with only 12% reinfestation. Antibody studies indicate, at this dosage, an antigenic stimulation that lasts at least 8 months, thus conferring a "vaccinating" action possible to be used with large population groups. Further studies show acceptable tolerance clinically of Oxamniquine and its ineffectiveness against S. haematobium. As mentioned by others, it appears that Oxamniquine has usefulness in treatment of schistosomiasis due to S. mansoni.

Adolescent↗